What changed for Vasculitis
A plain English summary of what recently moved in the public data Voxsanity tracks for Vasculitis. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting at Australian sites 5 to 2 (-3)
- Trials recruiting worldwide 153 to 142 (-11)
- Late-stage (Phase 3) trials 12 to 10 (-2)
- Trials on record 667 to 583 (-84)
Newly subsidised on the PBS
No medicines were newly subsidised on the PBS for Vasculitis in July 2026. Voxsanity tracks 1 PBS-subsidised medicine for this condition; none of them was listed for the first time this month.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 42 trials tracked for Vasculitis that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT01917721 · results posted 3 June 2026
According to the results reported on ClinicalTrials.gov, this trial looked at a treatment called doxycycline (an antibiotic) compared to a placebo (a dummy treatment with no active ingredient) in children with Kawasaki disease, a condition that can cause inflammation of the blood vessels including the arteries around the heart. A total of 26 children took part — 15 in the doxycycline group and 11 in the placebo group. The trial's main focus was on measuring changes in the size of the coronary arteries (the arteries that supply blood to the heart) over roughly four weeks, using a standardised s...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03557060 · results posted 18 February 2026
According to the results reported on ClinicalTrials.gov, this trial followed people in Japan who had been diagnosed with a condition called EGPA (eosinophilic granulomatosis with polyangiitis — a rare disease affecting blood vessels). A total of 4,115 people were enrolled, of whom 836 were included in the main safety analysis. The trial was an observational study tracking real-world use of a medicine called mepolizumab (NUCALA), and it measured three things: how many participants experienced side effects thought to be linked to the medicine, how many participants' doctors rated the treatment a...
-
NCT03906227 · results posted 26 November 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled a very small number of participants — just seven people in total across three groups. The groups were defined by levels of a particular immune cell marker called CD5+ and whether participants were receiving maintenance treatment. One person was in the "Low CD5+, on Maintenance" group, four were in the "High CD5, on Maintenance" group, and two were in the "High CD5, No Maintenance" group. The trial was measuring how long it took for a condition called vasculitis (inflammation of blood vessels) to return after a period...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03725202 · results posted 7 March 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03725202) enrolled 429 adults with giant cell arteritis (GCA) — an inflammatory condition affecting blood vessels, particularly in the head. Participants were randomly divided into three groups: 112 received a placebo (dummy pill) alongside a 52-week course of corticosteroids (a type of steroid medicine used to reduce inflammation); 107 received a lower dose (7.5 mg) of a drug called upadacitinib alongside a shorter 26-week corticosteroid course; and 210 received a higher dose (15 mg) of upadacitinib alongside the same sho...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04671446 · results posted 30 January 2025
According to the results reported on ClinicalTrials.gov, this study enrolled 120 people across four groups: 63 people with severe eosinophilic asthma (a type of asthma involving high levels of certain white blood cells), 30 healthy volunteers, 17 people with a condition called EGPA (a rare inflammatory disease also involving those same white blood cells), and 10 people with other respiratory conditions. All 120 participants completed the study. The trial was investigating whether people in these groups carry certain "autoantibodies" — proteins the immune system produces that can mistakenly tar...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02703922 · results posted 13 December 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 165 people who were suspected of having a condition called giant cell arteritis (GCA) — an inflammation of the arteries, particularly around the temples. Participants were divided into two groups based on the result of a colour Doppler ultrasound (CDU) scan, a type of imaging that looks at blood flow in arteries: 73 people whose scan result was "positive" (suggesting GCA) and 92 whose result was "negative." The trial was measuring how accurately the CDU scan identified people who truly had the condition, and also look...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04882072 · results posted 2 December 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04882072) studied ustekinumab as a treatment for Takayasu arteritis — a rare condition where the immune system attacks the body's large blood vessels. The trial enrolled 14 participants in total: 8 were assigned to receive a placebo first, then ustekinumab, and 6 received ustekinumab throughout. The trial ran in two stages — a blinded phase (where participants didn't know which treatment they were receiving) lasting roughly 71 weeks, followed by an open-label extension (where everyone received ustekinumab) of a further 63...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04551989 · results posted 19 September 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 118 people diagnosed with a rare inflammatory condition called eosinophilic granulomatosis with polyangiitis (EGPA), sometimes known as a type of blood vessel inflammation linked to high levels of a particular white blood cell. All participants received a medicine called mepolizumab at a dose of 300 mg. The trial was primarily tracking any unwanted medical events (called adverse events) that participants experienced during the study, as well as looking at things like disease flare-ups, hospital visits, and changes in...
-
NCT04413149 · results posted 17 May 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled two groups of participants: 31 people in the MPA-ILD group (a condition involving lung disease linked to a type of blood vessel inflammation) and 49 people in the ANCA-IIP group (a related lung condition). The trial was tracking two main outcomes over the study period — how many participants died from any cause, and how many received a lung transplant. The reported data shows that in the MPA-ILD group, 10 out of 31 participants died from any cause during the study, and 1 participant received a lung transplant. In the...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02179853 · results posted 4 March 2024
According to the results reported on ClinicalTrials.gov, this trial looked at a medicine called anakinra, given at three different daily dose levels. A total of 22 people took part — 4 in the lowest dose group (2–4 mg/kg/day), 3 in the middle dose group (5–7 mg/kg/day), and 15 in the highest dose group (8–11 mg/kg/day). All 22 participants who started the trial completed it. The reported data shows that the trial's primary (main) focus was on recording how many participants experienced adverse events — meaning any unwanted or unexpected health changes noted during the study. The numbers repor...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03827018 · results posted 17 October 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT03827018) looked at a medicine called mavrilimumab for people with a condition called giant cell arteritis (GCA), which is an inflammation of blood vessels. A total of 70 people took part — 42 received mavrilimumab and 28 received a placebo (a dummy treatment with no active ingredient). The main thing the trial was measuring was how long it took for participants' symptoms to flare up again over a 26-week period. Participants also followed a steroid-tapering schedule during the study. The reported data shows that for the p...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02222155 · results posted 16 August 2023
According to the results reported on ClinicalTrials.gov, this trial involved 42 people in total across three groups: 13 received a placebo (a dummy treatment) twice daily alongside standard care, 13 received a low dose (10 mg) of an investigational drug called CCX168 twice daily alongside standard care, and 16 received a higher dose (30 mg) of CCX168 twice daily alongside standard care. The trial was studying people with a condition called ANCA-associated vasculitis — an illness where the body's immune system attacks blood vessels. The trial was measuring how often unwanted health events occur...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03765788 · results posted 26 April 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT03765788) looked at a condition called Giant Cell Arteritis (GCA) — an inflammatory condition affecting blood vessels, particularly in the head. The trial enrolled 52 people in total: 27 received the study drug secukinumab and 25 received a placebo (a dummy treatment with no active ingredient). Both groups also took a steroid called prednisolone, which was gradually reduced over the course of the study. The trial's main goal was to measure how many participants stayed in "remission" — meaning they had no return of GCA symp...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02994927 · results posted 9 September 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT02994927) enrolled 331 people in total — 165 in the prednisone group and 166 in the avacopan group — all of whom had a condition called ANCA-associated vasculitis, a disease where the immune system attacks small blood vessels. The trial was measuring whether participants reached "remission" (meaning no signs of active disease, based on a standard scoring tool called BVAS, and no need for steroid treatment) at two points in time: 26 weeks and 52 weeks. Around 150–151 people in each group completed the study. The reported d...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03895801 · results posted 25 August 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT03895801) enrolled 57 people across three groups who had a form of inflammatory blood vessel disease called vasculitis. The three groups were: 18 people who received a drug called IFX-1 alongside a placebo (inactive substitute) for steroid tablets; 24 people who received a placebo for IFX-1 alongside a standard dose of steroid tablets (called glucocorticoids, or GC); and 15 people who received IFX-1 alongside a reduced dose of steroid tablets. The trial's main goal was to measure how many people in each group achieved a me...
-
NCT03712345 · results posted 26 May 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT03712345) enrolled 20 people in total, split across three groups: 6 received a high dose of IFX-1, 7 received a low dose of IFX-1, and 7 received a placebo (an inactive treatment given for comparison). Nearly all participants finished the study — one person in the placebo group did not complete it. The trial was primarily measuring how many participants experienced a treatment-emergent adverse event (TEAE), meaning any unwanted medical event that occurred after the treatment began. It also looked at a number of secondary m...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03026504 · results posted 8 April 2022
According to the results reported on ClinicalTrials.gov, this trial enrolled 15 people, all in a single group, who received a medicine called baricitinib. Fourteen of the 15 participants completed the study, while one did not finish. The trial was looking at a condition called Giant Cell Arteritis (GCA) — a type of blood vessel inflammation — and was measuring things like unwanted side effects, whether the condition came back (called a "relapse"), and blood markers that can indicate inflammation in the body. The reported data shows that 93% of participants (roughly 13 or 14 out of 15) experie...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01697267 · results posted 18 March 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT01697267) enrolled 170 people in total — 85 in a group receiving rituximab as a maintenance treatment and 85 in a group receiving azathioprine as a maintenance treatment. The trial was measuring how well each treatment kept a disease called ANCA-associated vasculitis (an inflammatory condition affecting blood vessels) in remission over time, and tracked things like disease flare-ups (relapses), ongoing remission, cumulative disease damage, steroid doses used, serious unwanted events, and infection rates. The reported data...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03600805 · results posted 14 January 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT03600805) enrolled 83 people with giant cell arteritis — a condition involving inflammation of blood vessels, particularly in the head. Participants were divided into four groups: two groups received a placebo (inactive) injection alongside a steroid (prednisone) that was gradually reduced over either 52 weeks or 26 weeks, and two groups received the medicine sarilumab (at different doses — 150 mg or 200 mg, given every two weeks) alongside the 26-week steroid taper. The trial was primarily measuring how many people in eac...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01363388 · results posted 27 July 2020
According to the results reported on ClinicalTrials.gov, this trial enrolled 67 people in total across three groups. One group (23 people) received a placebo tablet twice daily alongside a higher dose of the steroid prednisone (60 mg). A second group (22 people) received the investigational drug CCX168 (30 mg twice daily) alongside a lower dose of prednisone (20 mg). A third group (22 people) received CCX168 (30 mg twice daily) with no prednisone at all. The trial was primarily measuring how many participants achieved a meaningful reduction in disease activity by Day 85 (roughly 12 weeks), usi...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03658889 · results posted 28 May 2020
According to the results reported on ClinicalTrials.gov, this study (NCT03658889) enrolled 308 patients who had been diagnosed with giant cell arteritis (GCA) — a condition affecting blood vessels — along with 69 doctors who treated them. The study was observational, meaning it was designed to map out the patient's journey from first symptoms through to diagnosis and treatment, rather than testing a new medicine. Of the 308 patients, 306 completed the study. The reported data shows that the median time between a patient first noticing signs or symptoms and receiving a GCA diagnosis was 1 mont...
-
NCT00987389 · results posted 26 May 2020
According to the results reported on ClinicalTrials.gov, this trial enrolled 704 people in total, split across four groups depending on whether they received plasma exchange (a procedure that filters the blood) and whether they received a standard or reduced dose of steroid-type medicines called glucocorticoids. The trial was measuring whether plasma exchange made a difference to serious outcomes — specifically, how many participants either died from any cause or developed end-stage kidney disease (meaning their kidneys had failed badly enough to need at least 12 weeks of ongoing kidney replac...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02084147 · results posted 29 October 2019
According to the results reported on ClinicalTrials.gov, this trial enrolled 72 participants, and all 72 completed the study with no drop-outs. The trial was comparing two types of body scanning technology — PET-CT (a combination of two well-known scan types) and PET-MRI (a newer combination) — to see how they measured up against each other. The study looked at things like image quality, how well each scan detected abnormalities, how long each approach took, and how much radiation exposure was involved. The reported data shows that five primary outcomes were planned to be measured: overall im...
-
NCT01431105 · results posted 4 June 2019
According to the results reported on ClinicalTrials.gov, this trial enrolled 34 participants, all of whom were in a single group receiving atorvastatin. All 34 participants completed the study, and none dropped out. The trial ran for six weeks and was measuring how many participants experienced a Serious Adverse Event (SAE) — meaning a significant, unexpected medical problem — during that time. The reported data shows that the only outcome measure recorded was the number of participants who experienced a Serious Adverse Event during the six-week study period. Out of 34 participants, 4 were re...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02531633 · results posted 31 May 2019
According to the results reported on ClinicalTrials.gov, this trial enrolled 161 people across five treatment groups in its first phase (Part A, lasting 52 weeks). Participants were testing a medicine called sirukumab (SIR) — given by injection under the skin at different doses and schedules — compared to a placebo (dummy injection), with all groups also taking a steroid called prednisone for varying lengths of time. The trial was studying giant cell arteritis (GCA), an inflammatory condition affecting blood vessels. The main thing being measured was how many people reached and stayed in "sust...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01450137 · results posted 12 February 2019
According to the results reported on ClinicalTrials.gov, this trial enrolled 30 participants in total — 20 received a medicine called tocilizumab and 10 received a placebo (a dummy treatment with no active ingredient). The trial was studying a condition where the body's immune system attacks blood vessels, and it was measuring things like whether the disease went into complete remission (meaning no active signs of disease), whether it stayed away without a relapse (a return of symptoms), how much steroid medication (prednisolone) participants needed over the course of the trial, and how long p...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01596335 · results posted 26 September 2018
According to the results reported on ClinicalTrials.gov, this trial involved 31 children in total — 16 who received a treatment called TA-650, and 15 who received a comparison treatment called polyethylene glycol-treated human immunoglobulin (referred to as VGIH). The trial was looking at how these two treatments compared in children with a condition called Kawasaki disease, a rare illness that causes inflammation in blood vessels. The main thing the trial measured was how many children's fevers came down within 48 hours of starting treatment. It also tracked how long fevers lasted and whether...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02169219 · results posted 17 August 2018
According to the results reported on ClinicalTrials.gov, this trial enrolled 20 people, all of whom received a combination of a steroid medicine (glucocorticoids) and a drug called rituximab. The trial was looking at whether this combination could bring a blood vessel disease called AAV (ANCA-associated vasculitis) under control. Of the 20 people who started, 14 completed the study, and 6 did not complete it (the reasons were not detailed in the reported data). The reported data shows that, for the main goal — having no signs of active disease and being completely off steroids at 6 months — 1...
-
NCT00278512 · results posted 2 August 2018
According to the results reported on ClinicalTrials.gov, this trial (NCT00278512) enrolled 7 participants in total. All 7 were assigned to receive an autologous stem cell transplant (where a person's own stem cells are collected and returned to them after treatment), while no participants were enrolled in the allogeneic stem cell transplant group (where stem cells come from a donor). The trial's primary focus was measuring survival — that is, how many participants were still alive. The reported data shows that 6 of the 7 participants in the autologous transplant group completed the study, wit...
-
NCT01663623 · results posted 17 April 2018
According to the results reported on ClinicalTrials.gov, this trial looked at a medicine called belimumab (given at a dose of 10 mg/kg) compared to a placebo (a dummy treatment with no active ingredient) in people with a condition involving blood vessel inflammation known as vasculitis. A total of 105 people took part — 52 in the placebo group and 53 in the belimumab group. The trial was mainly measuring how long it took for participants to experience a "relapse," meaning a return or worsening of their condition. The reported data shows that for the primary outcome — time to first relapse — t...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
See all 42 reported results for Vasculitis
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, a substantial amount of public research funding has been directed toward vasculitis in the United States. However, the direction of that funding has been falling year on year, which may mean that some of the foundational scientific questions are considered answered, or that research priorities are shifting elsewhere. For patients, this is worth watching, as sustained...
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.